Hospital da Luz Setúbal will participate in its first clinical trial in the area of oncology, destined to patients with breast cancer in early stage: “Elacestrant Versus Standard Endocrine Therapy in Women and Men with ER+, HER2-, Early Breast Cancer with High Risk of Recurrence ( ELEGANT )”. This is a phase 3 clinical trial, international and multicentric, which will be conducted locally by oncologist Gonçalo Fernandes , with the collaboration of other physicians and health professionals and with the support of Hospital da Luz Learning Health. Along the trial, an experimental drug will be administered to selected patients, which will be evaluated in terms of efficiency, therapeutical benefit and safety, compared to the standard treatments presently available. Patients being followed at Hospital da Luz Setúbal and meeting the established criteria to participate in the clinical trial will be identified and recruited by the clinical team. For Hospital da Luz Setúbal, this is an important milestone in its path in the area of clinical research and oncology, as well as in terms of commitment to innovation and excellence in the provision of healthcare. In the other hand, this trial takes a symbolic nature being launched in full Pink October , the month of fight against breast cancer. Clinical trials: Represent the final stage in the process of development of a drug, being fundamental for scientific advancement and the improvement of healthcare. In phase 3 clinical trials, such as this conducted at Hospital da Luz Setúbal, the purpose is to demonstrate the efficacy and safety of a new drug compared to the standard treatment and confirm its potential therapeutical benefit. More information on clinical trials conducted within the Hospital da Luz Network .
